Cargando…
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies
Autores principales: | Pincez, Thomas, Bruneau, Julie, Berteloot, Laureline, Piekarski, Eve, Thomas, Caroline, Marçais, Ambroise, Trinquand, Amélie, Castelle, Martin, Garcelon, Nicolas, Plantaz, Dominique, Cheminant, Morgane, Moshous, Despina, Molina, Thierry Jo, Hermine, Olivier, Macintyre, Elizabeth, Fischer, Alain, Blanche, Stéphane, Suarez, Felipe, Neven, Bénédicte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556515/ https://www.ncbi.nlm.nih.gov/pubmed/33054064 http://dx.doi.org/10.3324/haematol.2019.230276 |
Ejemplares similares
-
Brentuximab Vedotin
Publicado: (2012) -
Choledochoduodenal Fistula during Chemotherapy with Brentuximab Vedotin for Methotrexate-associated Lymphoproliferative Disorder
por: Eso, Yuji, et al.
Publicado: (2018) -
Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022) -
P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023) -
Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)